Engitix appoints two additional international biotech industry leaders as Scientific Advisors
25 juin 2024 04h00 HE
|
Engitix Therapeutics
LONDON, June 25, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences
21 mai 2024 04h25 HE
|
Engitix Therapeutics
LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...
Engitix Announces Appointment of Christopher Stevenson, Ph.D., as Chief Scientific Officer
05 sept. 2023 07h00 HE
|
Engitix Therapeutics
LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary...
Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director
09 mai 2023 04h00 HE
|
Engitix Therapeutics
LONDON, May 09, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...